WO2006011363A1 - 粘着性マイクロベシクルの除去方法 - Google Patents
粘着性マイクロベシクルの除去方法 Download PDFInfo
- Publication number
- WO2006011363A1 WO2006011363A1 PCT/JP2005/012932 JP2005012932W WO2006011363A1 WO 2006011363 A1 WO2006011363 A1 WO 2006011363A1 JP 2005012932 W JP2005012932 W JP 2005012932W WO 2006011363 A1 WO2006011363 A1 WO 2006011363A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- microvesicles
- antibody
- circulating
- albumin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 31
- 239000000853 adhesive Substances 0.000 title claims description 17
- 230000001070 adhesive effect Effects 0.000 title claims description 17
- 210000004369 blood Anatomy 0.000 claims abstract description 51
- 239000008280 blood Substances 0.000 claims abstract description 51
- 108010088751 Albumins Proteins 0.000 claims abstract description 22
- 102000009027 Albumins Human genes 0.000 claims abstract description 22
- 238000005259 measurement Methods 0.000 claims description 21
- 230000001900 immune effect Effects 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 108090000288 Glycoproteins Proteins 0.000 claims description 6
- 102000003886 Glycoproteins Human genes 0.000 claims description 6
- 238000000691 measurement method Methods 0.000 claims description 5
- 108010090054 Membrane Glycoproteins Proteins 0.000 claims description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- UYNCFCUHRNOSCN-FYYLOGMGSA-N N-[(1R,2R)-1-hydroxy-3-(4-morpholinyl)-1-phenylpropan-2-yl]decanamide Chemical compound C([C@@H](NC(=O)CCCCCCCCC)[C@H](O)C=1C=CC=CC=1)N1CCOCC1 UYNCFCUHRNOSCN-FYYLOGMGSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 102000013415 peroxidase activity proteins Human genes 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 101000942694 Bos taurus Clusterin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001071312 Homo sapiens Platelet glycoprotein IX Proteins 0.000 description 1
- 101001070790 Homo sapiens Platelet glycoprotein Ib alpha chain Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102100036851 Platelet glycoprotein IX Human genes 0.000 description 1
- 102100034173 Platelet glycoprotein Ib alpha chain Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
Definitions
- the present invention does not affect the measurement of circulating microvesicles present in blood before blood sampling by using an adhesive micromouth vesicle that occurs in a blood-derived sample for microvesicle measurement.
- the present invention relates to a pre-treatment method, an appropriate measurement method for circulating microvesicles, and a measurement reagent or measurement kit thereof.
- Microvesicles are released from activated platelets during thrombus formation such as atherosclerosis and disseminated intravascular coagulation.
- the microvesicles promote blood coagulation by binding and concentrating clotting factors to phospholipids on the membrane surface, activating action of monocytes / platelets / vascular endothelial cells, or leukocytes / platelets / leukocytes / white blood cells.
- ⁇ Endothelial cells Known to promote adhesion of leukocytes, etc., and are thought to be deeply involved in thrombus formation and progression of arteriosclerosis, which is not just simple platelet activation (see Non-Patent Document 1).
- microvesicles are easily activated by physical stimulation or the like, and accordingly, the micromouth vesicles are released after the activation.
- the physical shock at the time of blood collection may increase microvesicles that do not reflect clinical status due to the activation of platelets mixed during the separation of plasma or serum in the blood-derived sample after blood collection.
- micro vesicles increase the amount of micro vesicles in blood-derived samples and hinder accurate determination of the patient's pathology. Therefore, there has been a demand for a method for accurately measuring microvesicles in blood before blood collection while eliminating the influence of microvesicles generated after blood collection.
- Non-Patent Document 1 Nomura S. Int. J. Hematol. 74, 397-404, (2001)
- the present invention provides a method for removing the adhesive microvesicles.
- the purpose of this study is to provide an appropriate measurement method and measurement reagent for circulating microvesicles in the blood using the above.
- microvesicles adheresive microvesicles
- albumin typified by BSA (usi serum albumin)
- BSA usi serum albumin
- Item 1 A method for pretreating a blood-derived sample to eliminate the influence of adhesive microvesicles in the blood-derived sample generated after blood collection, wherein albumin is added to the blood-derived sample.
- Item 2 The method according to Item 1, wherein the albumin is BSA.
- Item 3 A process to eliminate the influence of adhesive microvesicles in blood-derived samples that are generated after blood collection by adding albumin to blood-derived samples, and to measure circulating microvesicles in blood-derived samples immunologically
- Immunological measurement of circulating microvesicles is performed by binding antibodies against circulating microvesicles to a microvesicle-specific surface epitope and measuring the resulting bound antibody levels. The method described in 1.
- Item 5 The method according to Item 4, wherein the surface epitope is on a glycoprotein of a circulating microvesicle.
- Item 6 The method according to Item 5, wherein the surface glycoprotein is Gp3 ⁇ 4-IX.
- Item 7 The measuring method according to Item 6, wherein the antibody is detected based on a label or an enzyme bound to the antibody.
- Item 8 After binding circulating microvesicles to the immobilized antibody to GpIX, Item 8. The method according to Item 7, which comprises a step of causing an antibody that recognizes Gplb on the microvesicle to act.
- Item 9 A kit for measuring circulating microvesicles in a blood-derived sample containing at least albumin, an anti-Gplb-labeled antibody and an anti-GpIX antibody.
- Item 10 The kit according to item 9, wherein the albumin is BSA.
- Item 11 The kit according to Item 9 or 10, wherein the plate is coated with an anti-GpIX antibody.
- microvesicles present in patient blood are referred to as “circulating microvesicles”, and microvesicles released by platelet force activated by human manipulation during or after blood collection. Is called “adhesive microvesicle” because of its affinity for albumin.
- the blood-derived sample to be used in the present invention refers to blood or a solution containing blood components prepared from blood, and a sample subjected to platelet removal operation is preferable.
- plasma can be mentioned, and includes a solution obtained by diluting the blood fraction with physiological saline or a buffer solution from the viewpoint of measurement.
- Albumin refers to albumin derived from humans or non-human mammals or birds. Examples of non-human mammals include ushi, horses, monkeys, dogs, magpies, mice, and the like. -Can be raised as a representative example.
- ushi serum albumin BSA
- HSA human serum albumin
- ovalbumin ovalbumin
- albumin addition it may be added to a blood-derived sample before measurement, or after an antibody is immobilized on a plate, for example, by ELISA.
- the form of addition is not particularly limited, but it can be added after it is dissolved in physiological saline or isotonic buffer before it is desired to add in a liquid state.
- the amount of albumin added it is desirable that the final concentration is 5% or more, for example, the final concentration is about 5 to 10%.
- Adhesive microvesicles released from artificially activated platelets interact with albumin, and the surface of the microvesicle membrane In contrast to immunoassay methods using antibodies that utilize antigens, they are excluded from the system and do not substantially affect the measurement of circulating mic vesicles.
- Circulating microvesicles in the original blood-derived sample are measured by an immunological measurement method using the characteristics of ordinary microvesicles that are not substantially affected by the albumin treatment. It is possible.
- an antibody against the epitope is used to measure and quantify the microvesicle by quantifying the molecule.
- Any technique can be used without limitation. For example, ELISA method, RIA method, or aggregation method can be exemplified.
- Preferred antibodies according to the present invention include antibodies against Gplb-GPIX conjugates and Z or glycoproteins containing individual glycoproteins Gp3 ⁇ 4 and GpIX.
- Other platelet-specific glycoproteins found on microvesicles include Gpla—Ila, GpIIb
- an antibody that binds to circulating microvesicles may be labeled per se, or a labeled anti-mouse immunity that specifically binds to a second antibody, such as a mouse monoclonal antibody (first antibody). Globulin may be used.
- a monoclonal antibody can be preferably used.
- the label used can be any component that can emit a signal, such as an enzyme (peroxidase, alkaline phosphatase, etc.), a chromophore, a fluorophore (FITC, etc.), a radioisotope, a colored particle, a dye, a colloidal metal. And so on.
- an enzyme peroxidase, alkaline phosphatase, etc.
- a chromophore a fluorophore (FITC, etc.
- FITC fluorophore
- radioisotope a radioisotope
- an ELISA method using BSA is taken as an example and described in detail below.
- the blood-derived component prepared as described above is added to each well of a 96-well plate that has been previously coated with an anti-GpIX antibody and subjected to a blocking operation using skim milk or the like, for example, 10 to 1501, and then a BSA solution To a final concentration of 5% or more. Thereafter, in order to adsorb newly generated sticky microvesicles to BSA, incubation is performed at room temperature or at 37 ° C., for example, for 1 hour or longer, preferably 4 hours or longer with shaking. Then, wash thoroughly with a washing solution, for example, about 0.02 to 0.1% Tween20 / PBS.
- a washing solution for example, about 0.02 to 0.1% Tween20 / PBS.
- Peroki Add a sidase-labeled anti-Gplb antibody, wash thoroughly with the same washing solution, add a substrate for the enzyme, and perform color development.
- the amount of circulating microvesicles can be quantified as the amount of chromogenic substrate generated by the enzymatic reaction using an antibody based on the membrane surface epitope Gp3 ⁇ 4—GpIX complex.
- adhesive microvesicles generated by human manipulation are trapped in BSA, and then unreacted with the antibody used through this series of immunizations. Only microvesicles can be measured.
- a circulating microvesicle measurement kit including various antibodies and reagents used in the above-described operation can be provided. Specifically, in order to efficiently remove adhesive microvesicles generated by human manipulation, albumin typified by BSA, or the solution, and microvesicles typified by antibodies to Gplb and GpIX Recognizing antibody against membrane surface protein complex (the recognition antibody is labeled with one or both of them), and further, if necessary, secondary antibody, enzyme substrate (using enzyme as label) Etc.) are included in the kit.
- the recognition antibody is Piotin-binding Gplb
- the measurement kit may contain peroxidase-labeled avidin as a secondary reagent.
- a circulating microvesicle measuring kit containing a substrate for the peroxidase can be provided.
- the adhesive microvesicles released by the activation of mixed platelets at the stage of the conventional blood treatment operation are pretreated with albumin for efficiency. It can be removed from the immunoassay system and circulating microvesicles originally present in blood can be measured.
- Fig. 1 shows an absorption test of adhesive microvesicles by BSA using artificially activated samples, samples from patients with high microvesicles, and normal samples. is there.
- Example 1
- Circulating microvesicles from healthy adult males with normal values, whole blood collected with 3.8% citrate (titrate) was stored in a refrigerator at 4 ° C for 12 hours, and new PDMP (adhesive microphone) was used. Cycle). Refrigerated whole blood (2 ml) was centrifuged at 3000 rpm / 20 min in a table centrifuge, and the supernatant (6001) was collected to obtain an active serum sample. The activity sample was diluted x2 and x4 with saline and subjected to ELISA measurement.
- PDMP Circulating microvesicles
- EDTA / ACD taenoic acid-dextrose solution
- EDTA / ACD blood was collected (2 ml) from healthy adult males with normal PDMP values, centrifuged at 3000 rpm / 20 min at room temperature in a tabletop centrifuge, and the supernatant (6001) was collected and subjected to ELISA measurement.
- glycoproteins present on the surface of the microvesicle membrane antibodies against platelet-specific molecules CD42b (GpIb) and CD42a (GpIX) (anti-CD42b antibody; NNKY5_5, anti-CD42a antibody; KMP-9) are used.
- a sandwich ELISA assay system was prepared. Add 96 ⁇ l of activated sample and high-value sample to 96-well microtiter plate for ELISA coated with anti-CD42a antibody (Corning: MaxiSorb), and then add 50 ⁇ 1 to each sample. PBS and 2.5%, 5%, 7.5%, and 10% BSA were added, and wells with final concentrations of 1.25%, 2.5%, 3.75%, and 5% BSA were prepared.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002573311A CA2573311A1 (en) | 2004-07-26 | 2005-07-13 | Method of removing adhesive microvesicles |
EP05765777A EP1780543A4 (en) | 2004-07-26 | 2005-07-13 | METHOD FOR SEPARATING ADHESIVE MICROVESICLES |
US11/632,946 US20080014570A1 (en) | 2004-07-26 | 2005-07-13 | Method Of Removing Adhesive Microvesicles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-217387 | 2004-07-26 | ||
JP2004217387A JP4029298B2 (ja) | 2004-07-26 | 2004-07-26 | 粘着性マイクロベシクルの除去方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006011363A1 true WO2006011363A1 (ja) | 2006-02-02 |
Family
ID=35786114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/012932 WO2006011363A1 (ja) | 2004-07-26 | 2005-07-13 | 粘着性マイクロベシクルの除去方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20080014570A1 (ja) |
EP (1) | EP1780543A4 (ja) |
JP (1) | JP4029298B2 (ja) |
KR (1) | KR100896396B1 (ja) |
CN (1) | CN1989412A (ja) |
AR (1) | AR054974A1 (ja) |
CA (1) | CA2573311A1 (ja) |
TW (1) | TW200606429A (ja) |
WO (1) | WO2006011363A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019060369A1 (en) * | 2017-09-20 | 2019-03-28 | Molecular Stethoscope, Inc. | METHODS AND SYSTEMS FOR DETECTION OF TISSUE DISORDERS |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2736726T3 (es) * | 2006-03-09 | 2020-01-07 | Aethlon Medical Inc | Eliminación extracorpórea de partículas microvesiculares |
WO2010134567A1 (ja) * | 2009-05-22 | 2010-11-25 | コニカミノルタホールディングス株式会社 | 血中遊離核酸の検出方法 |
JP6210004B2 (ja) * | 2013-04-09 | 2017-10-11 | 株式会社Jvcケンウッド | 試料分析用デバイス及びエクソソームの捕捉方法 |
JP6210009B2 (ja) * | 2013-09-30 | 2017-10-11 | 株式会社Jvcケンウッド | 試料分析用基板及び基板分析装置 |
JP6201856B2 (ja) * | 2013-11-29 | 2017-09-27 | 株式会社Jvcケンウッド | 分析用基板及び分析用基板の製造方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003533698A (ja) * | 2000-05-16 | 2003-11-11 | ビオシテクス | 血小板由来微小粒子分析用のモノ試薬 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2187616A1 (en) * | 1994-04-15 | 1995-10-26 | Hoechst Celanese Corporation | Biocompatible coated article |
AR001654A1 (es) * | 1995-04-19 | 1997-11-26 | Univ East Carolina | Método para la descontaminacion microbiana de plaquetas sanguineas |
US6391575B1 (en) * | 1999-03-05 | 2002-05-21 | Idun Pharmaceuticals, Inc. | Methods for detecting membrane derived caspase activity and modulators thereof |
US20020076445A1 (en) * | 2000-02-10 | 2002-06-20 | Crowe John H. | Eukaryotic cells and method for preserving cells |
KR100502275B1 (ko) * | 2002-09-04 | 2005-07-20 | 바디텍메드 주식회사 | 면역분석법을 이용한 혈청 효소의 정량적 측정방법 및 이방법을 이용한 간질환 검사방법 |
WO2005110494A2 (en) * | 2004-05-04 | 2005-11-24 | The Board Of Trustees Of The University Of Illinois | Methods and compositions for the inhibition of thrombus formation |
-
2004
- 2004-07-26 JP JP2004217387A patent/JP4029298B2/ja active Active
-
2005
- 2005-07-13 KR KR1020077004315A patent/KR100896396B1/ko not_active IP Right Cessation
- 2005-07-13 EP EP05765777A patent/EP1780543A4/en not_active Withdrawn
- 2005-07-13 US US11/632,946 patent/US20080014570A1/en not_active Abandoned
- 2005-07-13 WO PCT/JP2005/012932 patent/WO2006011363A1/ja active Application Filing
- 2005-07-13 CN CNA2005800253451A patent/CN1989412A/zh active Pending
- 2005-07-13 CA CA002573311A patent/CA2573311A1/en not_active Abandoned
- 2005-07-20 TW TW094124488A patent/TW200606429A/zh unknown
- 2005-07-26 AR ARP050103083A patent/AR054974A1/es unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003533698A (ja) * | 2000-05-16 | 2003-11-11 | ビオシテクス | 血小板由来微小粒子分析用のモノ試薬 |
Non-Patent Citations (7)
Title |
---|
BROBERG M. & NYGREN H. ET AL: "Von Willebrand factor, a key protein in the exposure of CD62P on platelets.", BIOMATERIALS., vol. 22, 2001, pages 2403 - 2409, XP004255103 * |
MATZDORFF A.C. ET AL: "Relative and absolute changes of activated platelets, microparticles and platelet aggregates after activation in vitro.", HAEMOSTASIS., vol. 28, 1998, pages 277 - 288, XP001023452 * |
NOMURA S. ET AL: "Function and clinical significance of pletelet-derived microparticles.", INT J HEMATOLOGY., vol. 74, no. 4, 2001, pages 397 - 404, XP002991725 * |
NOMURA S., INT. J. HEMATOL., vol. 74, 2001, pages 397 - 404 |
OSUMI K. ET AL., THROMB. HAEMOST., vol. 85, 2001, pages 326 - 330 |
OSUMI K. ET AL: "Development and assessment of enzyme immunoassay for patelet-derived microparticles.", THROMB HAEMOST., vol. 85, 2001, pages 326 - 330, XP002979230 * |
See also references of EP1780543A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019060369A1 (en) * | 2017-09-20 | 2019-03-28 | Molecular Stethoscope, Inc. | METHODS AND SYSTEMS FOR DETECTION OF TISSUE DISORDERS |
GB2582074A (en) * | 2017-09-20 | 2020-09-09 | Molecualr Stethoscope Inc | Methods and systems for detecting tissue conditions |
Also Published As
Publication number | Publication date |
---|---|
AR054974A1 (es) | 2007-08-01 |
CN1989412A (zh) | 2007-06-27 |
CA2573311A1 (en) | 2006-02-02 |
US20080014570A1 (en) | 2008-01-17 |
EP1780543A4 (en) | 2007-11-28 |
JP2006038567A (ja) | 2006-02-09 |
JP4029298B2 (ja) | 2008-01-09 |
EP1780543A1 (en) | 2007-05-02 |
KR20070051284A (ko) | 2007-05-17 |
KR100896396B1 (ko) | 2009-05-08 |
TW200606429A (en) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5768371B2 (ja) | 血液試料の複数分析 | |
US5482841A (en) | Evaluation of transplant acceptance | |
WO2010104937A2 (en) | Lateral flow strip and uses thereof | |
JP3887340B2 (ja) | ノロウイルス又はサポウイルス検体用希釈液及びウイルス検出試薬 | |
US20090104634A1 (en) | One-step immunoassays exhibiting increased sensitivity and specificity | |
WO2006011363A1 (ja) | 粘着性マイクロベシクルの除去方法 | |
JP3422491B2 (ja) | 方法およびアッセイ | |
CN108680756A (zh) | 一种不完全抗体检测试剂盒及检测方法 | |
KR20160119166A (ko) | 활성 간염 바이러스 감염의 탐지용 콤보-간염 항원 분석 및 키트 | |
CN108700572A (zh) | 用于定量生物试样中的胆汁酸的试剂盒及定量生物试样中的胆汁酸的方法 | |
JPH02501948A (ja) | 粒子含有試料中の分析物の検出 | |
JP2016524691A (ja) | 血小板同種抗原タイピング及び血小板抗体試験 | |
JP2012168012A (ja) | 血管内皮障害を検査するための新規な検査方法および検査用キット | |
JP4464048B2 (ja) | 血液細胞抗原および該抗原に対して指向される抗体の検出方法 | |
Wolf et al. | Detection of antibodies interacting with glycosaminoglycan polysulfate in patients treated with heparin or other polysulfated glycosaminoglycans | |
TWI387751B (zh) | 用於RhD血型檢驗之套組及使用該套組以檢驗RhD血型之方法 | |
WO1986005591A1 (fr) | Procede de determination immunologique d'une substance biologique dans un echantillon | |
NL2016301B1 (en) | Method for detecting a marker for active tuberculosis. | |
JPH11502307A (ja) | 競合的結合アッセイ | |
JP2020052028A (ja) | イムノクロマト用試験片 | |
JP5137880B2 (ja) | 結合性物質を固定化した乾燥粒子の製造方法 | |
NO153987B (no) | Fremgagsmaate for bestemmelse av celletype eller forenlighet paa en fast matrise. | |
JP2018529085A (ja) | 血液試料または吸引試料中の上皮細胞の濃度を決定するための方法 | |
US20100267055A1 (en) | One-step immunoassays exhibiting increased sensitivity and specificity | |
WO2012032766A1 (ja) | 血中可溶型gpviを用いたアルツハイマー病の診断方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 12007500020 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2573311 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005765777 Country of ref document: EP Ref document number: 200580025345.1 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077004315 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11632946 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005765777 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11632946 Country of ref document: US |